NTRA

Natera, Inc. NMS · NTRA

$264.44 +1.81 (+0.69%)

Neutral · +0.14σ

+ Compare Open in Sniper

Mkt cap $37.9B

P/E —

Day $255.65 – $268.71

52wk $181.00 – $288.04

Avg vol 1.5M

Beta 1.50

Div yld —

Next earnings 2026-08-06

Quick read

Plain English

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.

NTRA last traded at $264.44, up 0.7% on the day; that's in the upper part of its 52-week range ($181.00–$288.04). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-08-06) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

above KC1 lower, +0.07 ATR from EMA21 — no notable pattern

Long —

score 16 · tech 16 / 80 · support 0 / 20

above KC1 lower, +0.07 ATR from EMA21 · no notable pattern

· Aligned with strong uptrend (strong tailwind)

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 6 · tech 6 / 80 · support 0 / 20

below KC1 upper, +0.07 ATR from EMA21 · no notable pattern

· Counter-trend short in strong uptrend

How this grade was earned

total 6 pts

Cycle position 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $58.72 (fair range $19–$59); today's price sits 360% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)

$58.72

Fair-value range

$19.12 – $58.72

Margin of safety

-360%

Verdict

Overvalued

Accounting quality Weak

✓ More cash than debt
✓ Quick ratio 3.14 (antifragile)
✓ Current ratio 3.39 (antifragile)
✓ Debt/equity 0.40 (antifragile)

⚠ Negative retained earnings
⚠ Inventory growing faster than revenue
⚠ Stock comp 15% of revenue (heavy dilution)

Price implies ~56% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

NTRA is a $37.9 billion company, it moves harder than the market (beta 1.5).

Mkt cap $37.9B

P/E ttm —

Fwd P/E -1291.9

Beta 1.50

Day range $255.65 – $268.71

52w range $181.00 – $288.04

Avg vol 1.5M

RSI(2) 32.1

ROE -15.0%

Net mgn -9.0%

FCF mgn 5.5%

Debt/Eq 0.14

Div yld —

Sector Healthcare

Industry Diagnostics & Research

Next earn 2026-08-06

52-week range · today's price

$181.00$288.04

More on NTRA

Options idea

See more →

CALL $270 2026-08-21

$19.20

PUT $280 2026-08-21

$27.40

Earnings

See more →

Last reported: 2026-05-07
EPS (act / est): -0.60 / -0.55
Surprise: -8.5%
Next report: 2026-08-06

About

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a ti…